SPADAFORA LINE-1-mediated chromatin remodeling of cancer cells (DSB.AD007.219)

Area tematica

Scienze biomediche

Area progettuale

Struttura responsabile del progetto di ricerca

Istituto di Farmacologia Traslazionale (IFT)

Altre strutture che collaborano al progetto di ricerca

• Istituto di biologia e patologia molecolari (IBPM)

Responsabile di progetto

CORRADO SPADAFORA
Telefono: 0649934486
E-mail: CORRADO.SPADAFORA@IFT.CNR.IT

Abstract

§ Abstract: Earlier work showed that reverse transcriptase (RT) inhibitors decrease the proliferation rate of cancer cells while non-cancer cells show limited sensitivity: this highlights the suitability of RT inhibitors as cancer-selective inhibitory drugs. Our results also revealed that RT inhibitors cause a remodeling of nuclear architecture in cancer cells, the induction of genome damage, alteration of the peripheral heterochromatin and fragmentation of the nuclear lamina. To clarify the mechanisms governed by RT inhibitors, we propose to investigate the subcellular localization and molecular interactors of RT-containing LINE-1 ORF2p. More specifically, we plan to localize ORF2p at peripheral heterochromatin, to assess its physical interaction with g-H2AX (DNA damage-specific histone variant) and with lamin B1 which undergoes fragmentation. This work sheds mechanistic light on RT inhibitors as cancer therapeutic drugs

Obiettivi

ND

Data inizio attività

13/05/2020

Parole chiave

LINE-1 RT, chromatin, cancer

Ultimo aggiornamento: 29/04/2024